22-23834262-C-T
Position:
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 10P and 1B. PM2PP5_Very_StrongBP4
The NM_003073.5(SMARCB1):c.*82C>T variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000776 in 1,288,604 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 33)
Exomes 𝑓: 7.8e-7 ( 0 hom. )
Consequence
SMARCB1
NM_003073.5 3_prime_UTR
NM_003073.5 3_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.109
Genes affected
SMARCB1 (HGNC:11103): (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1) The protein encoded by this gene is part of a complex that relieves repressive chromatin structures, allowing the transcriptional machinery to access its targets more effectively. The encoded nuclear protein may also bind to and enhance the DNA joining activity of HIV-1 integrase. This gene has been found to be a tumor suppressor, and mutations in it have been associated with malignant rhabdoid tumors. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Dec 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 22-23834262-C-T is Pathogenic according to our data. Variant chr22-23834262-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 239481.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr22-23834262-C-T is described in Lovd as [Pathogenic].
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.77). . Strength limited to SUPPORTING due to the PP5.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SMARCB1 | NM_003073.5 | c.*82C>T | 3_prime_UTR_variant | 9/9 | ENST00000644036.2 | NP_003064.2 | ||
SMARCB1 | NM_001362877.2 | c.*82C>T | 3_prime_UTR_variant | 9/9 | NP_001349806.1 | |||
SMARCB1 | NM_001317946.2 | c.*82C>T | 3_prime_UTR_variant | 9/9 | NP_001304875.1 | |||
SMARCB1 | NM_001007468.3 | c.*82C>T | 3_prime_UTR_variant | 9/9 | NP_001007469.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SMARCB1 | ENST00000644036.2 | c.*82C>T | 3_prime_UTR_variant | 9/9 | NM_003073.5 | ENSP00000494049.2 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD4 exome AF: 7.76e-7 AC: 1AN: 1288604Hom.: 0 Cov.: 20 AF XY: 0.00000156 AC XY: 1AN XY: 640946
GnomAD4 exome
AF:
AC:
1
AN:
1288604
Hom.:
Cov.:
20
AF XY:
AC XY:
1
AN XY:
640946
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:4Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 03, 2020 | In silico analysis, which includes splice predictors and evolutionary conservation, suggests this variant may impact gene splicing; however, transcript analysis found that SMARCB1 c.*82C>T did not induce abnormal splicing, but the variant was associated with reduced expression (Smith 2012b); This variant is associated with the following publications: (PMID: 22949514, 18647326, 19582488, 19320657, 25631985, 27921248, 25857641, 22434358, 28365909, 24933152) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 01, 2023 | This variant occurs in a non-coding region of the SMARCB1 gene. It does not change the encoded amino acid sequence of the SMARCB1 protein. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individuals with schwannomatosis (PMID: 18647326, 22434358, 24933152). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 239481). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this variant affects SMARCB1 function (PMID: 22949514). RNA analysis performed to evaluate the impact of this variant on mRNA splicing indicates it does not significantly alter splicing (Invitae). For these reasons, this variant has been classified as Pathogenic. - |
Schwannoma;C4024276:Peripheral schwannoma Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jan 01, 2017 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 17, 2023 | The c.*82C>T pathogenic mutation is located in the 3' untranslated region (3’ UTR) of the SMARCB1 gene. This variant results from a C to T substitution 82 nucleotides downstream of the last translated codon. This variant has been observed in multiple individuals with diagnosed with schwannomatosis (Boyd C et al. Clin Genet, 2008 Oct;74:358-66; Smith MJ et al. Neurogenetics, 2012 May;13:141-5; Smith MJ et al. Cancer Genet, 2014 Sep;207:373-8; Piotrowski A et al. Hum Mutat, 2022 Jan;43:74-84). It has also been reported to segregate with disease in related individuals (Boyd C et al. Clin Genet, 2008 Oct;74:358-66; Asai K et al. Brain Tumor Pathol, 2015 Jul;32:216-20). This alteration is reported to have reduced expression of the SMARCB1 transcript compared to the wild-type (Smith MJ et al. Hum Mol Genet, 2012 Dec;21:5239-45). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is pathogenic for SMARCB1-related schwannomatosis and tumor predisposition syndrome; however, the association of this alteration with Coffin-Siris syndrome is unknown. - |
SMARCB1-related schwannomatosis Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at